Trial Profile
Safety of bevacizumab in the radiation treatment of recurrent malignant glioma: A pilot study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma
- Focus Adverse reactions
- 22 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 13 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.